Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price reached a new 52-week low during trading on Monday . The company traded as low as C$0.98 and last traded at C$1.00, with a volume of 139671 shares changing hands. The stock had previously closed at C$1.07.
Wall Street Analysts Forecast Growth
Separately, Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday, November 14th.
Check Out Our Latest Stock Report on ONC
Oncolytics Biotech Stock Down 4.4 %
The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The stock has a market cap of C$83.78 million, a P/E ratio of -2.87 and a beta of 1.35. The company's 50 day moving average price is C$1.22 and its two-hundred day moving average price is C$1.36.
Oncolytics Biotech (TSE:ONC - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported C($0.12) EPS for the quarter, missing analysts' consensus estimates of C($0.11) by C($0.01). During the same period in the prior year, the company posted ($0.14) EPS. Equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
